MBX Biosciences, Inc. (NASDAQ:MBX) Given Average Recommendation of “Moderate Buy” by Brokerages

MBX Biosciences, Inc. (NASDAQ:MBX) has received a consensus recommendation of “Moderate Buy” from the twelve analysts that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation and ten have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $51.5556.

MBX has been the topic of a number of recent analyst reports. UBS Group reaffirmed a “buy” rating on shares of MBX Biosciences in a research report on Tuesday. The Goldman Sachs Group began coverage on MBX Biosciences in a report on Thursday, December 4th. They set a “sell” rating and a $18.00 price objective on the stock. Barclays initiated coverage on MBX Biosciences in a report on Tuesday, January 27th. They issued an “overweight” rating and a $66.00 target price for the company. Guggenheim raised their price target on MBX Biosciences from $77.00 to $88.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of MBX Biosciences in a research note on Thursday, January 22nd.

MBX Biosciences Price Performance

Shares of MBX opened at $32.55 on Friday. The firm has a market capitalization of $1.46 billion, a P/E ratio of -13.62 and a beta of 0.87. MBX Biosciences has a 52-week low of $4.81 and a 52-week high of $44.89. The company has a 50 day simple moving average of $35.96.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of MBX. GF Fund Management CO. LTD. acquired a new position in MBX Biosciences in the fourth quarter valued at $28,000. Russell Investments Group Ltd. grew its holdings in shares of MBX Biosciences by 4,131.4% during the third quarter. Russell Investments Group Ltd. now owns 1,481 shares of the company’s stock worth $26,000 after buying an additional 1,446 shares during the last quarter. Royal Bank of Canada increased its position in MBX Biosciences by 59.6% in the 4th quarter. Royal Bank of Canada now owns 1,532 shares of the company’s stock valued at $49,000 after acquiring an additional 572 shares during the period. FNY Investment Advisers LLC purchased a new stake in MBX Biosciences during the 3rd quarter valued at approximately $27,000. Finally, California State Teachers Retirement System lifted its position in MBX Biosciences by 64.7% during the 4th quarter. California State Teachers Retirement System now owns 1,754 shares of the company’s stock worth $55,000 after acquiring an additional 689 shares during the period.

About MBX Biosciences

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.